BioWorld

July 29, 2013

Ligand Dusts Off Lasofoxifene, Signs 2 Deals for Pfizer Castoff

A few years after Ligand Pharmaceuticals Inc. regained the rights to its selective estrogen receptor modulator (SERM) lasofoxifene from Pfizer Inc., the company has dusted off the osteoporosis drug and found new parties interested in moving the molecule forward. Read More

Dormant Stem Cells Reveal Secrets About Skin Aging

It is a popular notion that on average we renew most of the cells in our body every seven years or so. Read More

Week in Review

Word on the Street

Week in Washington

Biotech Mergers And Acquisitions: March 1 - July 25, 2013#

Money Raised By Biotech In 2013 vs. 2012

Money Raised By Biotech: Jan. 1 - July 25, 2013

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026

Hengrui discovers new Nav1.8 blockers

BioWorld Science

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...

Hematopoietic stem cell research points to leukemia’s early roots

BioWorld Science

Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...

Illustration of a nerve cell with DNA double helix

Molecular signatures show subtypes in neurodegenerative diseases

BioWorld Science

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...